ImmunoGen, Inc.

Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.

Oxford BioTherapeutics announced that Boehringer Ingelheim has selected a third drug candidate targeting OB33 to advance into IND-enabling studies under their ongoing collaboration.

Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company.

Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams.

CytomX's EpCAM-targeting antibody-drug conjugate CX-2051 demonstrated a 28% confirmed response rate in late-line colorectal cancer patients, significantly outperforming current standard therapies with single-digit response rates.

Cantargia's anti-IL1RAP antibody-drug conjugate demonstrated potent anti-tumor activity across different IL1RAP expression levels in preclinical models, with a single dose achieving 100% survival in high-expressing tumors.

The Federal Circuit has affirmed that ImmunoGen's patent application for a specific dosing regimen of mirvetuximab soravtansine (IMGN853) was obvious, despite the inventors' claim of solving an unknown ocular toxicity problem.

The European Commission has granted marketing authorization to AbbVie's Elahere for treating folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer.

AbbVie's Elahere (mirvetuximab soravtansine) receives EU approval for folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer, marking a significant advancement in treatment options.

The European Commission has approved AbbVie's Elahere for treating folate receptor-alpha (FRα) positive, platinum-resistant ovarian cancer in adults after one to three prior systemic treatments.